The closing price of Nevro Corp (NYSE: NVRO) was $12.70 for the day, up 1.68% from the previous closing price of $12.49. On the day, 523832 shares were traded.
Ratios:
Our analysis of NVRO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.94 and its Current Ratio is at 6.37. In the meantime, Its Debt-to-Equity ratio is 0.76 whereas as Long-Term Debt/Eq ratio is at 0.74.
On January 12, 2024, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $23 to $20.
Canaccord Genuity Downgraded its Buy to Hold on December 21, 2023, while the target price for the stock was maintained at $23.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 07 ’23 when McCormick Shawn bought 7,500 shares for $22.88 per share. The transaction valued at 171,633 led to the insider holds 26,866 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.09 while its Price-to-Book (P/B) ratio in mrq is 1.58.
Stock Price History:
Over the past 52 weeks, NVRO has reached a high of $39.67, while it has fallen to a 52-week low of $12.34.
Shares Statistics:
A total of 36.36M shares are outstanding, with a floating share count of 34.60M. Insiders hold about 4.95% of the company’s shares, while institutions hold 105.43% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by STRATEGY SHARES HALT CLIMATE CH analysts. The consensus estimate for the next quarter is $123.45, with high estimates of $12.70 and low estimates of $7,657.00.
Analysts are recommending an EPS of between $Healthcare and $Consumer Cyclical for the fiscal current year, implying an average EPS of $Healthcare.
